187 related articles for article (PubMed ID: 30214190)
1. Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles.
Kim JS; Kim MW; Kang SJ; Jeong HY; Park SI; Lee YK; Kim HS; Kim KS; Park YS
Int J Nanomedicine; 2018; 13():4817-4830. PubMed ID: 30214190
[TBL] [Abstract][Full Text] [Related]
2. Anti-EGFR immunonanoparticles containing IL12 and salmosin genes for targeted cancer gene therapy.
Kim JS; Kang SJ; Jeong HY; Kim MW; Park SI; Lee YK; Kim HS; Kim KS; Park YS
Int J Oncol; 2016 Sep; 49(3):1130-8. PubMed ID: 27573867
[TBL] [Abstract][Full Text] [Related]
3. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA.
Gao J; Chen H; Yu Y; Song J; Song H; Su X; Li W; Tong X; Qian W; Wang H; Dai J; Guo Y
Biomaterials; 2013 Dec; 34(38):10084-98. PubMed ID: 24060417
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells.
Deng L; Zhang Y; Ma L; Jing X; Ke X; Lian J; Zhao Q; Yan B; Zhang J; Yao J; Chen J
Int J Nanomedicine; 2013; 8():3271-83. PubMed ID: 24023515
[TBL] [Abstract][Full Text] [Related]
6. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
7.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs.
Lee YK; Lee TS; Song IH; Jeong HY; Kang SJ; Kim MW; Ryu SH; Jung IH; Kim JS; Park YS
Cancer Gene Ther; 2015 Jul; 22(7):335-43. PubMed ID: 25857361
[TBL] [Abstract][Full Text] [Related]
9. Sendai viroplexes for epidermal growth factor receptor-directed delivery of interleukin-12 and salmosin genes to cancer cells.
Kim JS; Kim MW; Jeong HY; Kang SJ; Park SI; Lee YK; Kim HS; Kim KS; Park YS
J Gene Med; 2016 Jul; 18(7):112-23. PubMed ID: 27191929
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.
Duan X; Mu M; Yan J; Bai L; Zhong L; Zhu Y; Pan H; Zhang M; Shi J
Int J Nanomedicine; 2018; 13():1443-1456. PubMed ID: 29563798
[TBL] [Abstract][Full Text] [Related]
11. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
Liu CW; Lin WJ
J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization of cancer cells by siRNA using targeted nanogel delivery.
Dickerson EB; Blackburn WH; Smith MH; Kapa LB; Lyon LA; McDonald JF
BMC Cancer; 2010 Jan; 10():10. PubMed ID: 20064265
[TBL] [Abstract][Full Text] [Related]
13. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
14. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
15. Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.
Cho HJ; Chong S; Chung SJ; Shim CK; Kim DD
Pharm Res; 2012 Apr; 29(4):1007-19. PubMed ID: 22169985
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
17. Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging.
Jeong HY; Kang SJ; Kim MW; Jeong IH; Choi MJ; Jung C; Song IH; Lee TS; Park YS
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339090
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
19. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma.
Lehtinen J; Raki M; Bergström KA; Uutela P; Lehtinen K; Hiltunen A; Pikkarainen J; Liang H; Pitkänen S; Määttä AM; Ketola RA; Yliperttula M; Wirth T; Urtti A
PLoS One; 2012; 7(7):e41410. PubMed ID: 22844475
[TBL] [Abstract][Full Text] [Related]
20. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
